Amarin Corporation

Amarin Corporation Forward P/E

The Forward P/E Ratio of Amarin Corporation (AMRN) as of Nov 19, 2026 is -8.01. In the previous year, Forward P/E Ratio was -3.78 — a change of 111.82% (lower).

Forward P/E

-8.01

YoY

111.82%

Last updated:

Forward P/E Ratio of Amarin Corporation is 2025 -8.01 . Forward P/E Ratio of Amarin Corporation was 2024 -3.78 . It decreases by 111.82% lower compared to the previous year.

The Amarin Corporation Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-2.67 USD
Jan 1, 2019
-13.73 USD
Jan 1, 2020
-17.27 USD
Jan 1, 2021
40.23 USD
Jan 1, 2022
-2.94 USD
Jan 1, 2023
-5.26 USD
Jan 1, 2024
-3.78 USD
Jan 1, 2025
-8.01 USD
The Amarin Corporation Forward P/E history
YEARForward P/EYoY
-8.01+111.82%
-3.78-28.07%
-5.26+78.99%
-2.94-107.31%
40.23-332.89%
-17.27+25.81%
-13.73+414.22%
-2.67-41.72%
-4.58+27.24%
-3.60+33.42%
-2.70-51.07%
-5.52—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amarin Corporation Stock analysis

What does Amarin Corporation do? Amarin Corporation PLC generates revenue primarily through the sale of Vascepa (icosapent ethyl) capsules, approved by the FDA for reducing triglyceride levels in patients with severe hypertriglyceridemia. The company sells Vascepa to wholesalers, regional wholesalers, and specialty pharmacy providers, collectively referred to as distributors, who then resell the product to retail pharmacies for patient and healthcare provider use. The MARINE indication, derived from the MARINE study, is the key approved use driving sales in the cardiovascular health segment. Amarin's commercial strategy centers on the Vascepa segment, focusing on the development and commercialization of this therapeutic. The firm's lead product, Vascepa, is positioned as an adjunct to diet for treating severe hypertriglyceridemia, targeting healthcare providers and patients through a distribution network of wholesalers and specialty pharmacies. This model ensures Vascepa reaches retail pharmacies where it is dispensed to end users. Amarin Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amarin Corporation stock

Forward P/E Ratio of Amarin Corporation is -8.01 in 2025.

Forward P/E Ratio of Amarin Corporation changed from -3.78 to -8.01, representing a 111.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Amarin Corporation since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Amarin Corporation with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Amarin Corporation

All Key Metrics — Amarin Corporation